

Supplementary Table 5. Summary of adverse events

	Teneligliptin (n=35)	Placebo (n=30)
Number of participants with TEAE	5 (14.3)	7 (23.3)
Serious AEs	1 (2.9)	0
Discontinuations because of AEs	0	0
Reported AEs		
Hypoglycemia	1 (2.9)	2 (6.7)
Blood creatinine increased	0	1 (2.9)
Blood urea increased	0	1 (2.9)
Electrocardiogram QT prolonged	1 (2.9)	0
Constipation	1 (2.9)	0
Pancreatitis chronic	1 (2.9)	0
Conjunctivitis	1 (2.9)	0
Cystitis	0	1 (2.9)
Blister	0	1 (2.9)
Pruritus	0	1 (2.9)
Cataract	0	1 (2.9)
Glucosuria	0	1 (2.9)
Myalgia	0	1 (2.9)

Values are presented as number (%).

TEAE, treatment-emergent adverse events; AE, adverse event.